Clinical Trials on Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Total 19 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

China, India, Thailand, Hong Kong, Korea, Republic of, Philippines
Novartis Pharmaceuticals

Completed

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (OLIMPIC)

Choroidal Neovascularization Secondary to Pathologic Myopia

Italy
Chengdu Kanghong Biotech Co., Ltd.

Unknown

A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV (SHINY)

Choroid Neovascularization Secondary to Degenerative Myopia

China
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

Choroidal Neovascularization Secondary to Pathologic Myopia

Korea, Republic of, China, Australia, Poland, Germany, Taiwan, Hong Kong
Novartis Pharmaceuticals

Completed

Observation of Treatment Patterns With Lucentis in Approved Indications (OCEAN)

Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV

Germany
University of Trieste

Unknown

Avastin for CNV Secondary to Pattern Dystrophy

Choroidal Neovascularization Secondary to Pattern Dystrophy

Italy
Novartis

Completed

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization (CNV) | Secondary to Age-related Macular Degeneration (AMD)

Germany, Belgium, Spain, Netherlands, United Kingdom, Hungary, Turkey, Israel, Portugal, Australia
Novartis

Completed

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Japan
Novartis Pharmaceuticals

Completed

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (FLUID)

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Australia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Pathological Myopia

Germany, India, Japan, Turkey, Austria, Switzerland, Italy, Lithuania, Hungary, France, Slovakia, United Kingdom, Korea, Republic of, Portugal, Hong Kong, Canada, Singapore, Spain, Latvia, Poland
Novartis Pharmaceuticals

Withdrawn

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (TIDE DME)

Visual Impairment Due to Diabetic Macular Edema

Germany
Novartis Pharmaceuticals

Withdrawn

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. (TIDE DME)

Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RELATION)

Visual Impairment Due to Diabetic Macular Edema

Germany
Helius Medical Inc

Recruiting

A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS) (PoNSTEP)

Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)

United States
A.O. Ospedale Papa Giovanni XXIII

Completed

An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications (SISCO)

Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection

Italy
Wroclaw Medical University

Completed

COVID-19 in Polish Ice Swimmers. (ICE)

Covid19 | Hypothermia | SARS-CoV Infection | Hypothermia Due to Cold Environment | Resistance, Disease

Poland
Amyndas Pharmaceuticals S.A.

Unknown

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) (SAVE)

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
OMNI Medical Services, LLC
OMNI Medical Services Inc

Recruiting

Outcomes Mandate National Integration With Cannabis as Medicine (OMNI-Can)

Depression | COVID-19 | Epilepsy | Multiple Sclerosis | Glaucoma | Cancer | Covid19 | Chronic Pain | Parkinson Disease | Inflammatory Bowel Diseases | Hepatitis C | Insomnia | HIV/AIDS | Amyotrophic Lateral Sclerosis | Fibromyalgia | Anxiety | Bipolar Disorder | Seizures | Crohn Disease | Traumatic Brain Injury | Ulcerative Colitis | Sickle... and other conditions

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Depression | Fatigue | Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone... and other conditions

United States

Clinical Trials on Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations